@

aianta phnrmnlimited

Ajanta House,

P +912266067200
E info@ajantaPharma.com

CharkoP, Kandivli West,

Mumbai400 067

lndia

9th

+91 22 6606 1000

www.ajantaPharma'com

January,2017

To,

1.

National Stock Exchange of India

Exchange Plaza,5th Floor, Plot no. C/1, G Block
Bandra Kurla Complex, Bandra (East)
Mumbai- 400 051

2.

BSE Limited
Phiroze Jeejeebhoy Towers
DalalStreet,
Mumbai - 400 001

Sub.: Receipt of ANDA approval from

US FDA
(Scrip Codes: NSE - AJANTPHARM EQ & BSE
AJANTPHARM 532331)

Dear Sir/Madam,

We are pleased to inform you that we have received the ANDA approval for
Duloxetine Hydrochloride Delayed Release Capsules from US FDA.
Press release being issued by us for the same is enclosed for your information
and records.
Thanking You,

Yours faithfully,

Gaurang Shah
Sr. GM - Legal & Company Secretary
Encl.: Press Release

Corporate ldentiW

Nu

mber - 124230MH 1979P1C022059

Ajanta House
Charkop, Kandivli West,
Mumbai 400 067
India

T +91 22 6606 1000

F +91 22 6606 1200
E info@ajantapharma.com
W www.ajantapharma.com

Press Release

Ajanta Pharma Announces US FDA Approval for

Duloxetine Hydrochloride Delayed Release Capsules
Mumbai, India (09th January, 2017) - Ajanta Pharma Limited, announces today the receipt
of final approval for Duloxetine Hydrochloride Delayed Release Capsules from US FDA*. It is
a bioequivalent generic version of Cymbalta1 Delayed Release Capsules. Company will be
launching the product shortly in 3 strengths, 20 mg, 30 mg and 60 mg strengths capsules.
Duloxetine Hydrochloride Delayed Release Capsules is part of an ever growing portfolio of
products that Ajanta has developed for the US market. In total, Ajanta has 32 Abbreviated
New Drug Application (ANDA) of which it has 17 final ANDA approvals, 2 tentative approvals
and 13 ANDAs under review with US FDA.
About Ajanta Pharma
Ajanta Pharma Limited is a specialty pharmaceutical formulation company with global
headquarters in Mumbai, India. Over 6,000 employees are engaged in developing,
manufacturing and marketing of quality finished dosages across 30+ countries.
For the financial year ended 31st March, 2016, Ajantas consolidated revenue stood at Rs.
1,728 cr. (USD 261 million) and net profit stood at Rs. 401 cr. (USD 61 million). For the last 5
years, Ajanta Pharma has posted healthy performance with its consolidated revenue growing
at 26% CAGR and net profit at 51% CAGR.
For more information on Ajanta Pharma Ltd., please visit www.ajantapharma.com and for
Ajanta Pharma USA Inc., please visit www.ajantapharmausa.com
For specific queries, contact:
Rajeev Agarwal Tel: +91 22 66061377 Email: rajeev.agarwal@ajantapharma.com
* United States Food & Drug Administration
1 Cymbalta is a registered trademark of Eli Lilly And Co.
Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331
Corporate Identity Number (CIN): L24230MH1979PLC022059

Safe Harbour Statement